Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma.

Cancer - 1 Nov 2013

Bucheit Amanda D, Syklawer Erica, Jakob John A, Bassett Roland L, Curry Jonathan L, Gershenwald Jeffrey E, Kim Kevin B, Hwu Patrick, Lazar Alexander J, Davies Michael A

Abstract excerpt

BACKGROUND: Hotspot mutations in BRAF and NRAS are the most common somatic events in patients with melanoma. These mutations occur at highly conserved residues, but include several different substitutions. To determine whether specific mutations are clinically important to differentiate, tumor characteristics and clinical outcomes were compared among patients with advanced melanoma with 1) BRAF V600E versus V600K...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cohort Studies
Share to DNA Mutational Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, ras

Share to Melanoma

Share to Neoplasm Metastasis

Share to Prognosis

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Source

Identifiers

PMID: 23922205
DOI: 10.1002/cncr.28306

Genes

BRAF
NRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma.PMID 23922205Read ↗

The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.Semantic proximity Read ↗

Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.Semantic proximity Read ↗

The molecular profile of metastatic melanoma in Australia.Semantic proximity Read ↗

Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients.Semantic proximity Read ↗

Effects of BRAF V600E and NRAS mutational status on the progression‑free survival and clinicopathological characteristics of patients with melanomaSemantic proximity Read ↗

Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis.Semantic proximity Read ↗

Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National Cohort.Semantic proximity Read ↗

BRAF, C-KIT, and NRAS mutations correlated with different clinicopathological features: an analysis of 691 melanoma patients from a single centerSemantic proximity Read ↗

Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.Semantic proximity Read ↗

Clinical characteristics and treatment outcomes of non-V600 E/K BRAF mutant melanoma patients: a single-institution experience.Semantic proximity Read ↗

The Impact of BRAF Mutational Status on Survival in Melanoma Patients: Single Centre Experience.Semantic proximity Read ↗

BRAF, NRAS and C-KIT Advanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.